Lyndon Lien - 27 Aug 2021 Form 4 Insider Report for Kindred Biosciences, Inc.

Role
Director
Signature
/s/ Lyndon Lien
Issuer symbol
N/A
Transactions as of
27 Aug 2021
Net transactions value
-$195,990
Form type
4
Filing time
30 Aug 2021, 14:40:50 UTC
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KIN Stock Option (right to buy) Disposed to Issuer $195,990 -47,000 -100% $4.17 0 27 Aug 2021 Common Stock 47,000 $5.08 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Lyndon Lien is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 This option provided for vesting in four equal quarterly installments from the option grant date. Pursuant to the agreement and plan of merger, dated as of June 15, 2021, by and among the Elanco Animal Health Incorporated, Knight Merger Sub, Inc., and Kindred Biosciences, Inc. (the "Merger Agreement"), the unvested portion of this option was subject to acceleration of vesting. This option was cancelled pursuant to the Merger Agreement in exchange for a cash payment of $195,990.00, representing the difference between the per share exercise price of the option and the merger consideration of $9.25 per share.